Oestrogen plays a major role in the mammary gland for duct elongation and branching, and also accelerates proliferation of epithelial cells. Responsiveness to oestrogen is retained after carcinogenesis in approximately 70% of all breast cancers. Mitogenic effects of oestrogens have been explained by two different mechanisms ([Gaben *et al*, 2004](#bib13){ref-type="other"}). Oestrogen can induce genomic effects through oestrogen-responsive elements located in the promoter region of c-fos ([Weisz and Rosales, 1990](#bib48){ref-type="other"}) and/or c-myc ([Dubik and Shiu, 1992](#bib10){ref-type="other"}) to affect mitogenic activity involving G1 phase progression, and oestrogen can also mediate indirect effects on cyclin D1 gene transcription ([Sabbah *et al*, 1999](#bib36){ref-type="other"}). Regulation of cyclin D1 gene transcription is strictly regulated in a hormone-dependant manner, and correspondingly, the cAMP response element in the promoter region of the cyclin D1 gene requires interaction with the AF-1 and AF-2 domains of oestrogen receptor (ER)*α*. Other non-genomic actions of oestrogen through mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and PI-3K/Akt signalling pathways have been debated ([Gaben *et al*, 2004](#bib13){ref-type="other"}). The effects of oestrogen binding to ERs represent a major target in the development of novel drugs and therapeutic strategies. Currently, adjuvant endocrine therapies are primarily based on targeting expression of hormone receptors ([Goldhirsch *et al*, 2007](#bib17){ref-type="other"}).

Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor, well characterised for its role in breast cancer. Specific ligands for HER2 have not been identified; however, dimer formation involving HER2, for example, a homodimer of HER2 or a HER2-HER3 heterodimer, have been shown to strongly activate intracellular signalling for cell proliferation, survival, motility, and adhesion ([Ross *et al*, 2004](#bib35){ref-type="other"}). Two major signalling pathways used by HER family receptors are the Raf/MEK/ERK pathway and the PI3K/PDK1/Akt pathway ([Navolanic *et al*, 2003](#bib31){ref-type="other"}). Downstream signalling from these pathways can affect regulation of gene expression to promote cell-cycle progression through inhibition of p27 ([Medema *et al*, 2000](#bib29){ref-type="other"}; [Delmas *et al*, 2001](#bib9){ref-type="other"}) and activation of cyclin D1 ([Cheng *et al*, 1998](#bib6){ref-type="other"}), or by inhibition of apoptosis through phosphorylation of Bad and caspase 9 ([Cardone *et al*, 1998](#bib3){ref-type="other"}). Human epidermal growth factor receptor-2 gene amplification is a poor prognostic factor in breast cancer ([Slamon *et al*, 1987](#bib39){ref-type="other"}) and plays an important role in resistance to hormone therapy and polychemotherapy experienced by HER2-positive cancer patients. However, HER2 gene amplification is predictive of a positive response to doxorubicin ([Paik *et al*, 1998](#bib32){ref-type="other"}) and trastuzumab (a humanised anti-HER2 antibody) ([Gaskell *et al*, 1992](#bib14){ref-type="other"}; [Cobleigh *et al*, 1999](#bib7){ref-type="other"}; [Slamon *et al*, 2001](#bib40){ref-type="other"}; [Vogel *et al*, 2002](#bib47){ref-type="other"}).

In contrast to ER-positive or HER2-positive breast cancers, mechanisms of cell proliferation and differentiation in breast cancers lacking ER and HER2 (ER(−)/HER2(−)) have not been well characterised. A hierarchical clustering study of gene expression by [Sorlie *et al* (2001](#bib41){ref-type="other"}, [2003)](#bib42){ref-type="other"} showed that breast cancers can be clustered into four subtypes: luminal, HER2-positive, basal-like, and normal breast-like, based on their expression patterns of ER, HER2, cytokeratin (CK)5/6, and other markers. The basal-like subtype is characterised by an absence of detectable ER and HER2 expression combined with positive expression of vimentin, epidermal growth factor receptor (EGFR), CK8/18, and CK5/6 ([Livasy *et al*, 2006](#bib26){ref-type="other"}). Tough 'basal-like subtype\' was an originally genotypic concept; increasing studies have refined the 'basal-like subtype\' as breast cancers with immunophenotype of ER/progesterone receptor (PgR)/HER2-negative breast cancers (triple-negative breast cancer; TNBC) and also positive for EGFR and/or CK5/6 expression ([Carey *et al*, 2006](#bib4){ref-type="other"}). On the other hand, TNBC expresses a basal phenotype in 56.0% of cases compared with non-TNBC (11.5%) ([Rakha *et al*, 2007](#bib34){ref-type="other"}). Thus, the relationship between breast cancers with a basal phenotype and TNBC has been identified. However, it is not fully understood how carcinoma cells can proliferate independent from ER or HER2 signalling pathways. This study focused on identifying molecules associated with cell proliferation or differentiation in ER-negative and HER2-negative breast cancers using oligonucleotide microarrays, quantitative reverse transcriptase--PCR (qRT--PCR), and genetic alteration studies including mutation analysis and fluorescence *in situ* hybridisation (FISH).

Materials and methods
=====================

Patients and tumour samples
---------------------------

A total of 40 samples, including 39 invasive ductal carcinomas and one ductal carcinoma *in situ*, were derived from immunohistochemically determined ER(+)/HER2(−), ER(+)/HER2(+), ER(−)/HER2(+), and ER(−)/HER2(−) tissue types. None of the patients providing the samples had received any pre-operative adjuvant hormone therapy or chemotherapy, and the patients were informed of the privacy policy of the study. The study design was approved by an institutional ethics committee. The incidence of the four immunohistochemistry (IHC) phenotypes were 6.9% ER(+)/HER2(+), 8.6% ER(−)/HER2(−), 14.8% ER(−)/HER2(+), and 69.7% ER(+)/HER2(−). Ten samples from each category were serially collected, snap frozen in liquid nitrogen, and stored at −80°C for microarray analysis. The remaining breast cancer samples were fixed in 10% formalin incubated within 48 h, embedded in paraffin, and subjected to immunohistochemical analysis as described below.

For analysis of E2F-5 expression, tumour samples of ER(−)/HER2(−) cancers were collected serially. In addition to 15 samples submitted for microarray analysis, which included 4 ER(+)/HER2(−), 4 ER(+)/HER2(+), 3 ER(−)/HER2(+), and 4 ER(−)/HER2(−) tissue samples, 15 ER(−)/HER2(−) cancers and 13 control samples (2 non-neoplastic mammary gland and 11 blood samples) were submitted for mutation analysis (43 total samples). For clinical and pathological analysis of E2F-5 expression, FISH and IHC assays were performed on 17 ER(−)/HER2(−) breast cancer samples in addition to 10 samples from each of the 4 breast cancer subtypes analysed by oligonucleotide microarray (57 total samples).

Microarray analysis
-------------------

Total RNA was isolated by phenol--chloroform extraction (Sepazol-I, Wako, Japan) from 100--200 mg of fresh frozen tissue. The extracted RNA was reverse transcribed to cDNA using T7-oligo-dT primer (synthesised by Qiagen Inc., Valencia, CA, USA) and converted to double-stranded DNA, which was used for synthesis of biotin-labelled cRNA using the MEGAscript *In Vitro* Transcript Kit (Ambion, Austin, TX, USA). The cRNA was fragmented and hybridised to oligonucleotide microarray chips (GeneChip® U95Av2, Affymetrix, Santa Clara, CA, USA), which contained 12 558 genes. Probe arrays were stained with streptavidin--phycoerythrin (Molecular Probes Inc., Eugene, OR, USA) and scanned. The intensity of each signal was captured with Affymetrix GeneChip Expression Analysis Software (LIMS5.0) according to Affymetrix\'s standard procedures, and was analysed with Excel (Microsoft Corp., Mountain View, CA, USA).

Gene expression data were log-transformed for further analysis. From the 7559 genes that were expressed at detectable levels in at least 3 samples, 831 genes with a coefficient of variation (standard deviation/mean) \>0.1 were identified as genes with significant variation in expression between different tumour types. The 831 genes were analysed by hierarchical cluster analysis using the software, Cluster (<http://rana.lbl.gov/EisenSoftware.htm>). Significant differential expression was defined as having a two-fold higher or lower change in expression level detected by IHC in ER(−)/HER2(−) tissue samples compared with other tumour subtypes, and IHC data were analysed using Welch\'s *t*-test and multistep two-way analysis of variance.

Quantative reverse transcriptase PCR (qRT--PCR)
-----------------------------------------------

Total RNA was isolated from frozen samples using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The integrity of the RNA was verified by electrophoresis. The first-strand cDNA was synthesised using SuperScript III First-Strand Synthesis System (Invitrogen). cDNA was subjected to real-time PCR analysis in an ABI PRISM 7700 Sequence Detector (Applied Biosystems Inc., Foster City, CA, USA) using the TaqMan approach. Sets of primers and fluorogenic probes specific for E2F5 were purchased from Applied Biosystems Inc. (Assay on Demand, Hs00231092_m1). The relative amount of target gene present was calculated based on the expression of human beta-actin representing an endogenous control (Applied Biosystems Inc.). Fluorescence was quantified by sequence detection system software (SDS, version 2.0, Applied Biosystems Inc.). Mean cycle threshold values (Ct) and standard deviation (s.d.) were calculated for E2F-5. The amount of target gene was normalised relative to the amount of the beta-actin \[ΔCt=ΔCt~(E2F−5)~−ΔCt~(beta−actin)~\] and the s.d. calculated \[s.d.(ΔCt)=√(SD~E2F−5~)^2^+(s.d. ~beta−actin~)^2^\]. The factor difference was also calculated (2^−ΔCt^). To calibrate the analysis, the value obtained from a non-neoplastic mammary gland was used as a control.

Direct sequencing
-----------------

The cDNA for direct sequencing was synthesised from isolated total RNA as described above. Sequencing was performed on both strands. Specific primers were designed to amplify a full length E2F5 cDNA (primer 1 for exon 2--6, forward 5′-AGTGGAAAGGTGTAGGTGC-3′, reverse 5′-CTGGATTTCTGTGGAGTCAC-3′; primer 2 for exon 3--8, forward 5′-AATGGTGATACACTTTTGGC-3′, reverse 5′-GAAGAACACTTCAGAATCAGTG-3′). Polymerase chain reactions were performed with 1 U HotStar Taq DNA polymerase (QIAGEN K.K., Tokyo, Japan) per 20 *μ*l. Polymerase chain reactions products were separated on an agarose gel, extracted, then run on an ABI 3100 Genetic Analyzer (Applied Biosystems Inc.). The results were analysed using DNASIS® Pro (Hitachi Software Engineering Co. Ltd, Tokyo, Japan).

Fluorescence *in situ* hybridisation
------------------------------------

An E2F-5 FISH probe was designed to hybridise to chromosome 8 ([Supplementary Figure 1](#sup1){ref-type="other"}) and bacterial artificial chromosome clone PR11-219B4 was obtained from BACPAC Resources (Children\'s Hospital Oakland Research Institute, Oakland, CA, USA). Bacterial artificial chromosome DNA was isolated using a Large-Construct kit (Qiagen Inc.) and labelled using a Nick Translation kit and Spectrum Orange dUTPs (Abbott Molecular Inc., Des Plaines, IL, USA). Fluorescence *in situ* hybridisation was performed using a centromere 8 (CEP8) DNA probe kit (Abbott Molecular Inc.) in combination with an E2F-5 probe according to the manufacturer\'s protocol. Signal numbers for the E2F-5 gene (labelled with SpectrumOrange) and CEP8 gene (labelled with SpectrumGreen) were counted in 60 carcinoma cells and plotted. An E2F-5/CEP8 signal ratio \>2.0 was interpreted as positive.

Immunohistochemistry and pathological evaluation
------------------------------------------------

Oestrogen receptor expression was stained using an automated machine (Benchmark, Ventana Japan, Yokohama, Japan), and HER2 expression was detected using a kit for HER2 (DAKO HercepTest, DakoCytomation, Carpinteria, CA, USA) in accordance with the manufacturer\'s instructions and the use of positive and negative controls. Antibodies used included anti-Ki-67 (clone MIB-1, DakoCytomation), anti-E2F-5 (polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-EGFR (clone 2-18C9, EGFR pharmDxKit, DakoCytomation), and anti-CK5/6 (Clone D5/16B4, DakoCytomation). Specificity of the anti-E2F-5 antibody was confirmed using an E2F-5 blocking peptide (SC-999 P, Santa Cruz Biotechnology) and by a single band at 59 kDa detected by immunoblotting. Immunohistochemical evaluation for HER2 was according to the manufacturer\'s recommendation. Oestrogen receptor and PgR were evaluated as positive with positive cells more than 10%, and EGFR and E2F-5 were evaluated as positive with any positive cells. Non-neoplastic tissues examined for E2F-5 expression included gastrointestinal organs, lung, kidney, ovary, uterus, prostate, testes, and brain. All of the samples were pathologically examined according to World Health Organization classification standards ([Tavassoli and Devilee, 2003](#bib43){ref-type="other"}) and the Scarff--Bloom--Richardson grading system ([Elston and Ellis, 1991](#bib12){ref-type="other"}). Breast cancers that were negative for expression of ER, PgR, and HER2 were determined to be 'TNBC\'. Alternatively, breast cancer samples lacking expression of ER, PgR, and HER2, while expressing EGFR and/or CK5/6, were considered to have a 'basal phenotype\' ([Carey *et al*, 2006](#bib4){ref-type="other"}).

Statistical analysis
--------------------

The χ^2^-test was used to evaluate the significance of clinicopathological characteristics compared between E2F-5-positive and -negative breast cancers with lymph node metastasis. The χ^2^-test was also used to analyse the immunohistochemical profiles of ER and HER2 expression. The Kruskal--Wallis test was used for data from tumour size and histological grade, and the Mann--Whitney test was used for data from Ki-67 labelling. Kaplan--Meier curves were used in survival analysis and the log-rank test was used for assessment of differences among multiple survival curves.

Results
=======

Genes differentially expressed in ER-negative/HER2-negative breast cancer samples
---------------------------------------------------------------------------------

In all, 17 genes differed in expression between the ER(−)/HER2(−) samples and the other breast cancer subtypes analysed (i.e. ER(+)/HER2(−), ER(+)/HER2(+), and ER(−)/HER2(+)). Eight genes were overexpressed (FABP7, GABRP, GAL, CXCL13, CDC42EP4, C2F, FOXM1, and CSDA), whereas nine genes showed decreased expression (ITGB5, KIAA0310, MAGED2, PRSS11, SORL1, TGFB3, KRT18, CPE, and BCAS1). None of the genes identified were directly related to cell proliferation proteins, such as cyclins, cyclin-dependant kinases, p53, p16, and the pRb and p21 families. When the candidate genes and their expression profiles for the ER(−)/HER2(−) samples and the ER-positive breast cancer samples, including ER(+)/HER2(−) and ER(+)/HER2(+) were compared, a subset of proteins were found to be overexpressed (CDKN2A (p16), E2F5, and CDC20), while CCND1 and GATA3 exhibited decreased expression in ER(−)/HER2(−) breast cancers ([Supplementary Table 1](#sup1){ref-type="other"}). One of the genes overexpressed in ER(−)/HER2(−) breast cancer tissues was a cell cycle-related transcription factor, E2F-5. Overexpression of E2F-5 was confirmed at the mRNA level by qRT--PCR ([Figure 1](#fig1){ref-type="fig"}). In addition, the expression level of E2F-5 significantly correlated with the level of Ki-67 expression only in ER(−)/HER2(−) samples (data not shown). The biological and clinicopathological significance of the role of E2F-5 in breast cancer has not been addressed earlier; therefore, we further investigated the role of E2F-5 in breast cancer.

E2F-5 gene amplification in breast cancers
------------------------------------------

Gene amplification of E2F-5 was examined by FISH. The mean signal numbers of CEP8 and E2F-5 were calculated and their ratio plotted ([Figure 2A](#fig2){ref-type="fig"}). Aneusomy of chromosome 8 was more frequent in ER(−)/HER2(−) breast cancers, and CEP8 had an increased signal number in ER(−)/HER2(−) breast cancers (2.0) compared with ER(+) breast cancers (1.51). E2F-5 gene amplification (E2F-5/CEP8 \>2.0) was detected in five breast cancer samples: two ER(−)/HER2(−), one ER(+)/HER2(−), one ER(+)/HER2(+), and one ER(−)/HER2(+). An example of E2F-5 gene amplification in a ER(−)/HER2(−) breast cancer sample is shown in [Figure 2B](#fig2){ref-type="fig"}.

Intracytoplasmic localisation of E2F-5 in normal tissues and breast cancers
---------------------------------------------------------------------------

Immunohistochemical studies detected E2F-5 in the cytoplasm of various epithelial and non-epithelial cells. E2F-5 was expressed in the smooth muscle cells of blood vessels and the intestinal wall, as well as in chondrocytes of the bronchial wall, in epithelial cells of the mucosal epithelium (stomach, colon, pancreatic duct, and gallbladder), in the squamous epithelium (skin and esophagus) ([Figure 3A](#fig3){ref-type="fig"}), and in hepatocyte and tubular epithelial cells. Intranuclear localisation of E2F-5 was less frequently detected in cardiomyocyte and smooth muscle cells of the gastrointestinal wall ([Figure 3B](#fig3){ref-type="fig"}). In the non-neoplastic mammary gland, a few ductal epithelial cells were positive for cytoplasmic E2F-5 expression ([Figure 3C](#fig3){ref-type="fig"}), whereas in the lactating mammary gland cells with nuclear expression of E2F-5 were detected in addition to cytoplasmic-positive cells ([Figure 3D](#fig3){ref-type="fig"}).

In the 19 breast cancer tissues positive for E2F-5, E2F-5 protein was only detected in the cytoplasm ([Figure 3E](#fig3){ref-type="fig"}), and the number of positive cells varied from tumour to tumour. Two ER(−)/HER2(−) tumour samples with E2F-5 gene amplification were positive for E2F-5, whereas three other tumour types (ER(+)/HER2(−), ER(+)/HER2(+), and ER(−)/HER2(+)) with E2F-5 gene amplification were negative for E2F-5.

Mutation analysis of E2F-5
--------------------------

E2F-5 is a transcription factor lacking a nuclear localisation signal ([Dyson, 1998](#bib11){ref-type="other"}); therefore, transportation of E2F-5 into the nucleus is supported by binding interactions with dimerisation protein (DP)3 or p130 proteins. We conducted a mutation analysis to determine whether a genetic mutation was present in the region of E2F-5 associated with the binding of transport proteins to affect the intracytoplasmic localisation of E2F-5 protein observed in the breast cancer subtypes. Only a synonymous mutation at codon 44 (GCG to GCC, Ala/Ala) was found in the DNA-binding domain of E2F-5. A polymorphism at this site was detected in 12 out of 13 control samples and in 28 out of 30 breast cancer tissues. Splicing variants with 3-bp deletions between exon 6 and exon 7 were also detected in all of the 13 control samples and the 30 breast cancer samples examined ([Supplementary Figure 2](#sup1){ref-type="other"}).

Clinicopathological characteristics of immunohistochemically E2F-5-positive breast cancers
------------------------------------------------------------------------------------------

We compared clinicopathological characteristics between immunohistochemically determined E2F-5-positive and -negative breast cancer samples ([Table 1](#tbl1){ref-type="table"}). There were no significant differences in tumour size, lymph node metastasis, or HER2 expression between these two groups. E2F-5-positive breast cancers exhibited a higher histological grade (*P*=0.049), were highly ER and PgR negative (*P*=0.039, *P*=0.010, respectively), and maintained a higher Ki-67 labelling index (*P*=0.001). Furthermore, we defined samples with negative expression of ER, PgR, and HER2 as 'TNBC\' samples, while TNBC samples expressing EGFR and/or CK5/6 were defined as 'basal phenotype\' samples. Our analysis showed that E2F-5-positive cancers were more frequent in TNBC (51.9%) samples than in non-TNBC (16.7%) samples (*P*=0.0049), were more frequent in breast cancer samples exhibiting a basal phenotype (56.0%) than in those exhibiting a non-basal phenotype (15.6%) (*P*=0.0012), and were more frequent in metaplastic carcinomas (*P*=0.0034) ([Table 1](#tbl1){ref-type="table"}).

Disease-free survival was extended in patients with node-negative/E2F-5-negative cancers (*n*=23) compared with node-negative/E2F-5-positive samples (*n*=15), node-positive/E2F-5-negative samples (*n*=13), and node-positive/E2F-5-positive samples (*n*=6) ([Figure 4](#fig4){ref-type="fig"}, *P*=0.014). In addition, in the lymph node-negative group, the E2F-5-positive subset exhibited a shorter disease-free survival period (*n*=13, *P*=0.013) than the E2F-5-negative group (*n*=23). There were no significant differences between ER-positive (*n*=12) and -negative groups (*n*=24, *P*=0.14), or between HER2-positive (*n*=10) and -negative groups (*n*=26, *P*=0.22).

Discussion
==========

This study has identified a subpopulation of breast cancer cells that overexpress the transcription factor E2F-5. We found E2F-5-positive breast cancers were more frequent in TNBC samples and also in samples exhibiting a basal phenotype with higher Ki-67 labelling indexes. Patients with node-negative/E2F-5-positive cancers also showed worse clinical outcomes with shorter disease-free survival periods. The biological and clinicopathological significance of E2F-5 expression in breast cancer has not been well documented, but we show here that overexpression of E2F-5 correlated with aggressive histological pathologies and a worse clinical outcome.

E2F-5 belongs to the E2F transcription factor family, which consists of eight members, E2F-1--8 ([La Thangue and Rigby, 1987](#bib23){ref-type="other"}; [Dyson, 1998](#bib11){ref-type="other"}). On the basis of sequence homology and function, E2F family members have been divided into three distinct groups: E2F-1--3 ([Helin *et al*, 1992](#bib18){ref-type="other"}; [Kaelin *et al*, 1992](#bib21){ref-type="other"}; [Shan *et al*, 1992](#bib38){ref-type="other"}; [Ivey-Hoyle *et al*, 1993](#bib20){ref-type="other"}; [Lees *et al*, 1993](#bib24){ref-type="other"}), E2F-4 and 5 ([Ginsberg *et al*, 1994](#bib16){ref-type="other"}; [Hijmans *et al*, 1995](#bib19){ref-type="other"}; [Sardet *et al*, 1995](#bib37){ref-type="other"}), and E2F-6 ([Morkel *et al*, 1997](#bib30){ref-type="other"}; [Cartwright *et al*, 1998](#bib5){ref-type="other"}; [Trimarchi *et al*, 1998](#bib44){ref-type="other"}). Heterodimers formed between E2F-1--3 and DPs have been shown to be strong transcriptional activators that can drive quiescent cells into S phase ([Kowalik *et al*, 1995](#bib22){ref-type="other"}; [DeGregori *et al*, 1997](#bib8){ref-type="other"}; [Lukas *et al*, 1997](#bib27){ref-type="other"}; [Verona *et al*, 1997](#bib46){ref-type="other"}). In addition, these heterodimers can stimulate the transcription of genes involved in cell-cycle control (cyclin A, cyclin E, pRb, p107, E2F-1), initiation of replication (Orc1, cdc6, MCM3), DNA synthesis (DNA polymerase, thymidylate synthesis, thymidine kinase, dihydrofolate reductase), and can also drive expression of proto-oncogenes (c-myb, B-myb, c-myc, N-myc) ([Campanero *et al*, 1999](#bib2){ref-type="other"}; [Trimarchi and Lees, 2002](#bib45){ref-type="other"}). In contrast, the functional roles of E2F-4 and 5 remain to be fully characterised. In studies of homozygous E2F-5 knockout embryos, despite an initial normal phenotype, the newborn mice go on to develop non-obstructive hydrocephalus from excessive production of cerebrospinal fluid. This phenotype supports a role for E2F-5 in differentiation of neural tissue rather than in cell proliferation ([Lindeman *et al*, 1998](#bib25){ref-type="other"}). In a separate study, murine embryonic fibroblasts derived from E2F-5 knockout mice were shown to proliferate normally and reenter the cell cycle from the G0 phase, but failed to arrest at the G1 phase in response to overexpression of p16 ([Lindeman *et al*, 1998](#bib25){ref-type="other"}; [Gaubatz *et al*, 2000](#bib15){ref-type="other"}). When the E2F-5 gene was cotransfected with DP-1 and Ras into baby rat kidney cells, an increased number of transformed foci were induced; thereby, suggesting an oncogenic role for human E2F-5 ([Polanowska *et al*, 2000](#bib33){ref-type="other"}). The results of our study further indicate that overexpression of E2F-5 correlates with an aggressive pathology of certain breast cancer subtypes.

Gene amplification of E2F-5 was detected in 5 out of 57 (8.8%) breast cancer samples examined in this study. It was intriguing that gene amplification of E2F-5 was accompanied by E2F-5 protein in ER(−)/HER2(−) breast cancer samples, whereas E2F-5 expression was not detected in other types of cancers that had undergone gene amplification. Although regulatory mechanisms of E2F-5 gene transcription have not been characterised beyond studies of E2F-5 overexpression at the mRNA and protein levels in ER(−)/HER2(−) breast cancers, we hypothesise that additional unknown factors are contributing to the transcription, translation, and gene amplification of E2F-5. [Macaluso *et al* (2003)](#bib28){ref-type="other"} reported that protein complexes, including pRb2/p130 and E2F-4/5, can regulate ER*α* gene transcription in breast cancer cell lines. Both the relationship between ER expression and the biological role of E2F-5, as well as the regulatory mechanisms of E2F-5 gene transcription require further investigation.

Although E2F-4 and -5 lack a nuclear localisation signal, they are still able to translocate from the cytoplasm into the nuclei by binding to pocket proteins (p107, p130) and/or DP-1, 2, 3 ([Dyson, 1998](#bib11){ref-type="other"}). E2F-5 has been shown to localise to the cytoplasm in asynchronous cultures of exponentially growing cells, and is recruited into the nucleus of serum-starved cells in a quiescent state ([Allen *et al*, 1997](#bib1){ref-type="other"}). We also observed localisation of E2F-5 to the nucleus in the G0 phase, whereas E2F-5 localised to the cytoplasm in the other cell-cycle phases (data not shown). If E2F-5 has a functional role in the G0 phase, how then can we explain the detection of a higher Ki-67 index in cells overexpressing E2F-5 in ER(−)/HER2(−) breast cancer samples? We originally hypothesised that intracytoplasmic localisation of E2F-5 in cancer cells was the result of genetic alterations, such as point mutations in the binding site of DP or other pocket proteins, and that dysfunction of E2F-5 could cause increased cell proliferation. However, mutation analysis failed to detect any alteration in amino-acid coding that would affect protein--protein interactions with E2F-5. There are several possible explanations for the accumulation of E2F-5 in the cytoplasm including (1) a failure of the nuclear transporting process or dysfunction of binding interactions between E2F-5 and pocket proteins, and DPs; (2) the inability of cells for G1 arrest of transition into G0 phase; or (3) a failure of E2F-5 to be metabolised through a pathway involving ubiquitination. To determine the role of these possibilities and their associated mechanisms would require further study.

In conclusion, we have shown that a subgroup of breast cancers overexpress a transcriptional factor, E2F-5, and that E2F-5-positive breast cancers were more common in TNBC and in breast cancers with a basal phenotype. In addition, these breast cancer subtypes were associated with a worse clinical outcome.

Supplementary Material {#sup1}
======================

###### Supplementary Figure 1

###### Supplementary Figure 2

###### Supplementary Figures Legend

We thank Mrs Yukiko Kirimura (Department of Pathology, Tokai University School of Medicine) for technical support for the experiments. Supported by a Grant-in-Aid for Scientific Research (C) (no. 15590317) from the Japanese Society for the Promotion of Science.

**Conflict of interest**

The authors do not have any conflict of interest in performing this study that could have biased the design of the experiments or the analysis of the results.

[Supplementary Information](#sup1){ref-type="other"} accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

![Quantification of E2F-5 mRNA levels by real-time RT--PCR. The expression level of E2F-5 is gradually higher in ER(+)/HER2(−), ER(+)/HER2(+), ER(−)/HER2(+), and ER(−)/HER2(−) breast cancer subtypes, respectively. ^\*^*P*=0.02 for ER(+)/HER2(−) *vs* ER(+)/HER2(+); ^\*\*^*P*=0.02 for ER(+) *vs* ER(−)/HER2(+); ^\*\*\*^*P*=0.04 for ER(+)/HER2(+) *vs* ER(−)/HER2(−).](6604900f1){#fig1}

![Labelling of centromere 8 and E2F-5 by fluorescence *in situ* hybridisation (FISH). (**A**) The number of CEP8 and E2F-5 signals from the FISH experiments are plotted on the *x*- and *y*-axis, respectively. Five tumours, plotted on the upper left side of the solid line, have an E2F-5/CEP8 signal ratio of \>2 and are therefore predicted to have undergone E2F-5 gene amplification. Data from the various breast cancer samples are labelled in the figure as follows: green circle dots -- ER(+)/HER2(−); blue circle dots -- ER(+)/HER2(+); orange circle dots -- ER(−)/HER2(+); pink circle dots -- ER(−)/HER2(−). Data from breast cancer cell lines (MCF-7, MDA-MB231) are indicated with purple square dots. (**B**) Centeromere 8 (CEP8) is labelled in green and E2F-5 is labelled in orange in ER(−)/HER2(−) cells.](6604900f2){#fig2}

![Immunohistochemical study of E2F-5 expression in non-neoplastic and breast cancer tissues. Detection of E2F-5 in (**A**) squamous epithelium and (**B**) non-epithelial smooth muscle cells. In non-neoplastic mammary gland tissue, positive cells are detected in a resting state in the cytoplasm (**C**) as well as in the lactating phases (**D**) indicated by arrows. An arrow head (**D**) and inset indicate positive cells in nucleus. E2F-5 is also shown expressed in the cytoplasm of carcinoma cells (**E**). All of the metaplastic cancers tested were positive for E2F-5 (**F**). Scale bar indicates a length of 50 *μ*m (**A**--**F**) and 10 *μ*m (inset).](6604900f3){#fig3}

![Kaplan--Meier survival analysis for patients with each of the four breast cancer subtypes analysed. (**A**) Disease-free survival was extended in the node-negative/E2F-5-negative cancer subtypes (blue, *n*=23) compared with the node-negative/E2F-5-positive subtype (pink, *n*=15), the node-positive/E2F-5-negative subtype (gray, *n*=13), and the node-positive/E2F-5-positive cancer subtype (green, *n*=6) (*P*=0.014). In the lymph node-negative subgroup (**B**--**D**), the E2F-5 positive group shows a shorter disease-free survival interval (pink, *n*=13, *P*=0.013) than the E2F-5-negative group (blue, *n*=23). There were no significant differences between the ER-positive (**C**; green, *n*=12) and -negative groups (**C**; blue, *n*=24, *P*=0.14), and the HER2-positive (**D**; orange, *n*=10) and -negative groups (**D**; blue, *n*=26, *P*=0.22).](6604900f4){#fig4}

###### 

Clinicopathological features of E2F-5-positive breast cancers

                                   **E2F-5**               
  -------------------------------- ----------- ----------- --------
  *Tumour size*                                            NS
   T1                              9           17           
   T2                              7           14           
   T3                              3           6            
                                                            
  *Lymph node metastasis*                                  NS
   Absent                          6           15           
   Present                         13          23           
                                                            
  *Histological grade*                                     0.049
   I                               0           6            
   II                              6           21           
   III                             13          11           
                                                            
  *Oestrogen receptor*                                     0.039
   Positive                        3           16           
   Negative                        16          22           
                                                            
  *Progesterone receptor*                                  0.010
   Positive                        2           17           
   Negative                        17          21           
                                                            
  *HER2*                                                   NS
   Positive                        5           14           
   Negative                        14          24           
                                                            
  *Pathological characteristics*                            
   TNBC                            14          13          0.0049
   Non-TNBC                        5           25           
                                                            
   Basal phenotype                 14          11          0.0012
   Non-basal phenotype             5           27           
                                                            
   Apocrine carcinoma              1           3           NS
   Metaplastic carcinoma           4           0           0.0034
                                                            
  Ki-67 labelling index (%)        59.5±20.4   36.3±26.3   0.001

NS=not significant; TNBC=triple-negative breast cancer (ER/PgR/HER2 negative).
